Ali Ünal

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 620 citations

Hematological Malignancy, Medicine, Immunology +6

A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer

H.Ş. Çoşkun, Özlem Er, Metin Özkan et al. · Journal of Thrombosis and Haemostasis · 2004 · 454 citations

Randomized Clinical Trial, Oncology, Combination Chemotherapy +8

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro et al. · The Lancet Oncology · 2021 · 316 citations

Hematological Malignancy, Oncology, Dexamethasone Versus Pomalidomide +7

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 231 citations · Full text

Regenerative Medicine, Cell Therapy, Transplantation +7

Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen—A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Arnon Nagler, Vanderson Rocha, Myriam Labopin et al. · Journal of Clinical Oncology · 2013 · 171 citations · Full text